Biologics for thyroid eye disease

Marius N. Stan; James A.Leon Garrity; Barbara G. Carranza; Thapa Prabin; Elizabeth A. Bradley; Rebecca S. Bahn; Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz; Jose V. Perez-Moreiras; Juan J. Gomez-Reino; Jose R. Maneiro; Eva Perez-Pampin; Angel Romo Lopez; Fernando M.Rodríguez Alvarez; Jesús M.Castillo Laguarta; Aurora del Estad Cabello; María Gessa Gregori Sorroche; Enrique España; Marco Sales-Sanz; Terry J. Smith; George J. Kahaly; Daniel G. Ezra; James C. Fleming; Roger A. Dailey; Rosa A. Tang; Gerald J. Harris; Alessandro Antonelli; Mario Salvi; Robert A. Goldberg; James W. Gigantelli; Steven M. Couch; Erin M. Shriver; Brent R. Hayek; Eric M. Hink; Richard M. Woodward; Kathleen Gabriel; Guido Magni; Raymond S. Douglas

doi:10.1007/978-3-030-92794-3_46

Biologics for thyroid eye disease

Marius N. Stan, James A.Leon Garrity, Barbara G. Carranza, Thapa Prabin, Elizabeth A. Bradley, Rebecca S. Bahn, Mario Salvi, Guia Vannucchi, Nicola Currò, Irene Campi, Danila Covelli, Davide Dazzi, Simona Simonetta, Claudio Guastella, Lorenzo Pignataro, Sabrina Avignone, Paolo Beck-Peccoz, Jose V. Perez-Moreiras, Juan J. Gomez-Reino, Jose R. ManeiroEva Perez-Pampin, Angel Romo Lopez, Fernando M.Rodríguez Alvarez, Jesús M.Castillo Laguarta, Aurora del Estad Cabello, María Gessa Gregori Sorroche, Enrique España, Marco Sales-Sanz, Terry J. Smith, George J. Kahaly, Daniel G. Ezra, James C. Fleming, Roger A. Dailey, Rosa A. Tang, Gerald J. Harris, Alessandro Antonelli, Mario Salvi, Robert A. Goldberg, James W. Gigantelli, Steven M. Couch, Erin M. Shriver, Brent R. Hayek, Eric M. Hink, Richard M. Woodward, Kathleen Gabriel, Guido Magni, Raymond S. Douglas

Ophthalmology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Biologic therapy, and particularly teprotumumab, can achieve disease-modifying response without the adverse effects of systemic steroids for active thyroid eye disease. The following manuscripts detail the evidence behind various steroid-sparing biologic agents for thyroid eye disease.

Original language	English (US)
Title of host publication	Foundational Papers in Oculoplastics
Publisher	Springer International Publishing
Pages	481-498
Number of pages	18
ISBN (Electronic)	9783030927943
ISBN (Print)	9783030927936
DOIs	https://doi.org/10.1007/978-3-030-92794-3_46
State	Published - Jan 31 2022

Keywords

Graves' disease
Hyperthyroidism
Rituximab
Teprotumumab
Thyroid eye disease
Tocilizumab

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-92794-3_46

Cite this

Stan, M. N., Garrity, J. A. L., Carranza, B. G., Prabin, T., Bradley, E. A., Bahn, R. S., Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., Beck-Peccoz, P., Perez-Moreiras, J. V., Gomez-Reino, J. J., ... Douglas, R. S. (2022). Biologics for thyroid eye disease. In Foundational Papers in Oculoplastics (pp. 481-498). Springer International Publishing. https://doi.org/10.1007/978-3-030-92794-3_46

Stan, MN, Garrity, JAL, Carranza, BG, Prabin, T, Bradley, EA, Bahn, RS, Salvi, M, Vannucchi, G, Currò, N, Campi, I, Covelli, D, Dazzi, D, Simonetta, S, Guastella, C, Pignataro, L, Avignone, S, Beck-Peccoz, P, Perez-Moreiras, JV, Gomez-Reino, JJ, Maneiro, JR, Perez-Pampin, E, Lopez, AR, Alvarez, FMR, Laguarta, JMC, del Estad Cabello, A, Sorroche, MGG, España, E, Sales-Sanz, M, Smith, TJ, Kahaly, GJ, Ezra, DG, Fleming, JC, Dailey, RA, Tang, RA, Harris, GJ, Antonelli, A, Salvi, M, Goldberg, RA, Gigantelli, JW, Couch, SM, Shriver, EM, Hayek, BR, Hink, EM, Woodward, RM, Gabriel, K, Magni, G & Douglas, RS 2022, Biologics for thyroid eye disease. in Foundational Papers in Oculoplastics. Springer International Publishing, pp. 481-498. https://doi.org/10.1007/978-3-030-92794-3_46

@inbook{3f4835611d07492bb696a73916e98535,

title = "Biologics for thyroid eye disease",

abstract = "Biologic therapy, and particularly teprotumumab, can achieve disease-modifying response without the adverse effects of systemic steroids for active thyroid eye disease. The following manuscripts detail the evidence behind various steroid-sparing biologic agents for thyroid eye disease.",

keywords = "Graves' disease, Hyperthyroidism, Rituximab, Teprotumumab, Thyroid eye disease, Tocilizumab",

author = "Stan, {Marius N.} and Garrity, {James A.Leon} and Carranza, {Barbara G.} and Thapa Prabin and Bradley, {Elizabeth A.} and Bahn, {Rebecca S.} and Mario Salvi and Guia Vannucchi and Nicola Curr{\`o} and Irene Campi and Danila Covelli and Davide Dazzi and Simona Simonetta and Claudio Guastella and Lorenzo Pignataro and Sabrina Avignone and Paolo Beck-Peccoz and Perez-Moreiras, {Jose V.} and Gomez-Reino, {Juan J.} and Maneiro, {Jose R.} and Eva Perez-Pampin and Lopez, {Angel Romo} and Alvarez, {Fernando M.Rodr{\'i}guez} and Laguarta, {Jes{\'u}s M.Castillo} and {del Estad Cabello}, Aurora and Sorroche, {Mar{\'i}a Gessa Gregori} and Enrique Espa{\~n}a and Marco Sales-Sanz and Smith, {Terry J.} and Kahaly, {George J.} and Ezra, {Daniel G.} and Fleming, {James C.} and Dailey, {Roger A.} and Tang, {Rosa A.} and Harris, {Gerald J.} and Alessandro Antonelli and Mario Salvi and Goldberg, {Robert A.} and Gigantelli, {James W.} and Couch, {Steven M.} and Shriver, {Erin M.} and Hayek, {Brent R.} and Hink, {Eric M.} and Woodward, {Richard M.} and Kathleen Gabriel and Guido Magni and Douglas, {Raymond S.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "31",

doi = "10.1007/978-3-030-92794-3_46",

language = "English (US)",

isbn = "9783030927936",

pages = "481--498",

booktitle = "Foundational Papers in Oculoplastics",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Biologics for thyroid eye disease

AU - Stan, Marius N.

AU - Garrity, James A.Leon

AU - Carranza, Barbara G.

AU - Prabin, Thapa

AU - Bradley, Elizabeth A.

AU - Bahn, Rebecca S.

AU - Salvi, Mario

AU - Vannucchi, Guia

AU - Currò, Nicola

AU - Campi, Irene

AU - Covelli, Danila

AU - Dazzi, Davide

AU - Simonetta, Simona

AU - Guastella, Claudio

AU - Pignataro, Lorenzo

AU - Avignone, Sabrina

AU - Beck-Peccoz, Paolo

AU - Perez-Moreiras, Jose V.

AU - Gomez-Reino, Juan J.

AU - Maneiro, Jose R.

AU - Perez-Pampin, Eva

AU - Lopez, Angel Romo

AU - Alvarez, Fernando M.Rodríguez

AU - Laguarta, Jesús M.Castillo

AU - del Estad Cabello, Aurora

AU - Sorroche, María Gessa Gregori

AU - España, Enrique

AU - Sales-Sanz, Marco

AU - Smith, Terry J.

AU - Kahaly, George J.

AU - Ezra, Daniel G.

AU - Fleming, James C.

AU - Dailey, Roger A.

AU - Tang, Rosa A.

AU - Harris, Gerald J.

AU - Antonelli, Alessandro

AU - Salvi, Mario

AU - Goldberg, Robert A.

AU - Gigantelli, James W.

AU - Couch, Steven M.

AU - Shriver, Erin M.

AU - Hayek, Brent R.

AU - Hink, Eric M.

AU - Woodward, Richard M.

AU - Gabriel, Kathleen

AU - Magni, Guido

AU - Douglas, Raymond S.

PY - 2022/1/31

Y1 - 2022/1/31

N2 - Biologic therapy, and particularly teprotumumab, can achieve disease-modifying response without the adverse effects of systemic steroids for active thyroid eye disease. The following manuscripts detail the evidence behind various steroid-sparing biologic agents for thyroid eye disease.

AB - Biologic therapy, and particularly teprotumumab, can achieve disease-modifying response without the adverse effects of systemic steroids for active thyroid eye disease. The following manuscripts detail the evidence behind various steroid-sparing biologic agents for thyroid eye disease.

KW - Graves' disease

KW - Hyperthyroidism

KW - Rituximab

KW - Teprotumumab

KW - Thyroid eye disease

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85156168997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85156168997&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-92794-3_46

DO - 10.1007/978-3-030-92794-3_46

M3 - Chapter

AN - SCOPUS:85156168997

SN - 9783030927936

SP - 481

EP - 498

BT - Foundational Papers in Oculoplastics

PB - Springer International Publishing

ER -

Biologics for thyroid eye disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this